SCYNEXIS Announces One-for-Eight Reverse Stock Split
Rhea-AI Summary
SCYNEXIS (NASDAQ: SCYX) approved a 1-for-8 reverse stock split of its common stock, effective 4:05 p.m. ET on May 29, 2026. Trading on a split-adjusted basis begins June 1, 2026 under the existing symbol with a new CUSIP.
The split aims to satisfy Nasdaq’s minimum bid price requirement and reduces authorized shares from 150 million to 18.75 million and outstanding shares from about 79.5 million to 9.9 million. Fractional shares will be paid in cash.
AI-generated analysis. Not financial advice.
Positive
- 1-for-8 reverse split targeting Nasdaq minimum bid price compliance
- Outstanding shares cut from ~79.5 million to ~9.9 million
- Authorized shares reduced from 150 million to 18.75 million
Negative
- Holders entitled only to fractional shares will receive cash instead of stock
- Stock options, RSUs and warrants see higher exercise prices after proportional adjustment
News Market Reaction – SCYX
On the day this news was published, SCYX declined 6.88%, reflecting a notable negative market reaction. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $58.10M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SCYX was up 6.32% pre-announcement, while peers were mixed: IXHL -1.09%, AYTU -0.24%, CPIX +0.55%, RMTI +1.10%, TLPH in momentum scanner at about -1.23%. Moves appear stock-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | Earnings & update | Positive | -5.3% | Q1 2026 results, SCY-770 acquisition plans, runway to mid-2029. |
| May 06 | Inducement grants | Neutral | -2.5% | Equity awards to new Vice President under inducement plan. |
| Mar 31 | Asset purchase terms | Positive | +16.1% | Acquisition terms for PXL770 (SCY-770) up to $196M total value. |
| Mar 31 | Private placement | Positive | +16.1% | $40M upfront private placement with potential extra $52.2M via warrants. |
| Mar 31 | Pipeline acquisition | Positive | +16.1% | Completion of transformative SCY-770 acquisition for ADPKD program. |
Recent fundamentally positive updates and financings have sometimes seen negative or muted next-day reactions, with only the March 31 cluster showing strong gains.
Over the last six months, SCYNEXIS has focused on financing and pipeline expansion. On Mar 31, 2026, it completed the PXL-770 (SCY-770) acquisition and a $40.0 million private placement, both followed by a +16.11% move. Subsequent filings added up to $196 million in potential deal value. However, Q1 2026 results and corporate update on May 11, 2026 saw a -5.35% reaction, and an inducement grant on May 6, 2026 also traded lower, indicating uneven responses to news. Today’s reverse split fits into efforts to stabilize listing status after these actions.
Regulatory & Risk Context
An effective S-3 shelf dated May 1, 2026 registers up to 87,000,000 shares of common stock for resale related to the March–April 2026 private placement. The company would only receive proceeds from any cash exercises of pre-funded warrants at $0.0001 per share and common warrants at $1.20 per share. A 424B3 prospectus on May 8, 2026 reflects recent usage.
Market Pulse Summary
The stock moved -6.9% in the session following this news. A negative reaction despite the mechanical nature of the 1‑for‑8 reverse split would fit a pattern where prior positive developments, such as Q1 updates on May 11, 2026, saw a -5.35% move. The split reduces outstanding shares from about 79.5M to 9.9M and follows an effective S-3 resale registration for 87M shares, so concerns about resale overhang and post-split volatility could weigh on sentiment.
Key Terms
reverse stock split financial
nasdaq capital market regulatory
cusip regulatory
special meeting regulatory
par value financial
restricted stock units financial
transfer agent financial
proxy statement regulatory
AI-generated analysis. Not financial advice.
SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026
JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026.
SCYNEXIS’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS’s existing trading symbol “SCYX” with a new CUSIP number, 811292 309.
The reverse stock split was approved by SCYNEXIS’s stockholders at SCYNEXIS’s Special Meeting held on May 19, 2026, with the final ratio subsequently determined by SCYNEXIS’ Board of Directors. The reverse stock split is intended to bring SCYNEXIS into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
At the effective time of the reverse stock split, every 8 shares of SCYNEXIS’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, and the authorized shares of SCYNEXIS’s common stock will be reduced from 150 million to 18.75 million shares, without any change in par value per share. The reverse stock split will reduce the number of issued and outstanding shares of common stock from approximately 79.5 million shares to approximately 9.9 million shares. The reverse stock split reduces the number of shares of common stock issuable upon the exercise or vesting of SCYNEXIS’s outstanding stock options, restricted stock units and warrants in proportion to the ratio of the reverse stock split and causes a proportionate increase in the exercise prices of such stock options and warrants, in accordance with their respective terms and as described in SCYNEXIS’s proxy statement for its Special Meeting of Stockholders as filed with the Securities and Exchange Commission on April 27, 2026 (the “Proxy Statement”).
No fractional shares of common stock will be issued as a result of the reverse stock split. Stockholders of record who would otherwise be entitled to receive a fractional share will receive a cash payment in lieu thereof. The reverse stock split impacts all holders of SCYNEXIS’s common stock proportionally and will not impact any stockholder’s percentage ownership of common stock (except to the extent the reverse stock split results in any stockholder owing only a fractional share).
SCYNEXIS has chosen its transfer agent, Equiniti Trust Company, LLC (the “Transfer Agent”), to act as exchange agent for the reverse stock split. Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take further action in connection with the reverse stock split, subject to brokers’ particular processes.
Additional information regarding the reverse stock split can be found in the Proxy Statement.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com.
Forward-Looking Statements
Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: the anticipated initiation of the SCY-770 Phase 2 study in Q4 of 2026 and the anticipated early efficacy readout in the second half of 2027, the plans to report topline data from the Phase 1 IV trial of SCY-247 in the second half of 2026 and the statements concerning expected extension of the company’s cash runway to the middle of 2029, and other statements identified by words such as “will,” “potential,” “could,” "can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. For the Company, this includes the future prospects of the Company’s SCY-770 program, the timing and results of the Company’s anticipated Phase 2 proof-of-concept clinical study evaluating SCY-770, stock price volatility and uncertainties relating to the financial markets, the medical community and the global economy, and the impact of instability in general business and economic conditions, including changes in inflation and interest rates. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation, its most recent Annual Report on Form 10-K filed on March 4, 2026, including under the caption "Risk Factors,” and in other filings the Company makes with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com
